Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1352 • ACR Convergence 2021
Deucravacitinib Efficacy in Psoriatic Arthritis (PsA) by Baseline DMARD Use: Exploratory Analysis from a Phase 2 Study
Atul Deodhar¹, Miroslawa Nowak², June Ye², Tom Lehman², Lan Wei², Subhashis Banerjee² and Philip Mease³, ¹Oregon Health & Science University, Portland, OR, ²Bristol Myers Squibb, Princeton, NJ, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: PsA presents with heterogeneous clinical manifestations including joint pain, enthesitis, dactylitis, and skin and nail lesions. Treatment guidelines recommend that PsA patients (pts) who…
Abstract Number: 1700 • ACR Convergence 2021
Pharmacokinetic Boosting to Enable Once-Daily Reduced Dose Tofacitinib
Céleste van der Togt¹, Lise Verhoef², Nathan den Broeder³, Rob ter Heine³, Bart van den Bemt⁴ and Alfons den Broeder⁵, ¹Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, ²Sint Maartenskliniek, Nijmegen, Netherlands, ³Radboud University Medical Centre, Nijmegen, Gelderland, Netherlands, ⁴Sint Maartenskliniek; Radboud University Medical Center, Ubbergen, Netherlands, ⁵Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands
Background/Purpose: Tofacitinib is an effective, yet costly, drug for treatment of RA and PsA. Tofacitinib is metabolized mainly by the cytochrome P450-enzyme CYP3A4, and the…
Abstract Number: 1787 • ACR Convergence 2021
What Is Peripheral SpondyloArthritis? Identifying Disease Phenotype and Burden: A Post Hoc Analysis of the ASAS-PerSpA International Study
Nelly Ziade¹, Joe Rassi², Bassel Elzorkany³, Clementina López Medina⁴, Sherif Gamal³, Sani Hlais⁵, Maxime Dougados⁶ and Xenofon Baraliakos⁷, ¹Rheumatology Department, Saint-Joseph Medical University and Hotel-Dieu de France Hospital, Beirut, Lebanon, ²Department of Orthopedic Surgery, Hotel-Dieu de France, Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon, ³Cairo University, Cairo, Egypt, Cairo, Egypt, ⁴Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, ⁵Department of Family Medicine, American University of Beirut/ Saint-Joseph University, Beirut, Lebanon, ⁶Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, ⁷Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Peripheral spondyloarthritis (pSpA) shows features that overlap with psoriatic arthritis (PsA), axial spondyloarthritis (axSpA) and other forms of SpA and is unsatisfactorily defined despite…
Abstract Number: 1804 • ACR Convergence 2021
Targeted Safety Analyses of Guselkumab (TREMFYA®): Long-term Results from Randomized Clinical Trials in Patients with Active Psoriatic Arthritis and Moderate to Severe Psoriasis
Philip Mease¹, Peter Foley², Kristian Reich³, Soumya Chakravarty⁴, May Shawi⁵, Ya-Wen Yang⁶, Megan Miller⁷, Alexa Kollmeier⁸, Xie Xu⁷, Jenny Yu⁷, Yanli Wang⁷, Shihong Sheng⁷, Yin You⁷ and Iain McInnes⁹, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²University of Melbourne, Carlton, Australia, ³University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁴Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, ⁵Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁶Janssen Global Services, LLC, Horsham, PA, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸Janssen Research & Development, LLC, La Jolla, CA, ⁹University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: Guselkumab (GUS), a human monoclonal antibody that specifically binds to the p19 subunit of IL-23, demonstrated efficacy and a favorable safety profile in active…
Abstract Number: 1822 • ACR Convergence 2021
Relationships Between Dermatologic Symptoms and Health-related Quality of Life in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
Peter C Taylor¹, Andrew G Bushmakin², Joseph C Cappelleri², Pamela Young³, Rebecca Germino², Joseph Merola⁴ and Gil Yosipovitch⁵, ¹University of Oxford, Oxford, United Kingdom, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA, ⁴Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ⁵University of Miami Miller School, Florida, FL
Background/Purpose: Dermatologic symptoms of PsA can substantially impact patient (pt) health‑related quality of life (HRQoL);1 itch is the most commonly reported, and among the most…
Abstract Number: 1943 • ACR Convergence 2021
Post-inflammatory and Degenerative Changes in Patients with Psoriatic Arthritis and Axial Manifestations: Post-hoc Analysis from a Double-blind, Randomized, Phase 3b Trial
Xenofon Baraliakos¹, Effie Pournara², Laura Coates³, Victoria Navarro-Compán⁴, Roisin White⁵, Barbara Schulz² and Robert Landewé⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Novartis Pharma AG, Basel, Switzerland, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁴Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ⁵Novartis Ireland Limited, Dublin, Ireland, ⁶Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands
Background/Purpose: Axial psoriatic arthritis (PsA) is the only one of the PsA manifestations, still not clearly defined, with no currently available universally acceptable clinical and…
Abstract Number: 0088 • ACR Convergence 2021
Evaluation of Patient Characteristics and Clinical Outcomes Among SARS‑CoV‑2‑Diagnosed Patients with and Without RA or PsA Treated with Systemic Therapies: A Retrospective Cohort Study Using US Optum® COVID-19 Electronic Health Record Data
Jeffrey Curtis¹, Xiaofeng Zhou², Jinoos Yazdany³, Philip Robinson⁴, Yan Chen², Ann Madsen², Jamie Geier² and Birgitta Benda², ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Pfizer Inc, New York, NY, ³University of California San Francisco, San Francisco, CA, ⁴Faculty of Medicine, The University of Queensland, Herston, Australia
Background/Purpose: Patients with chronic rheumatic diseases are considered to be at increased risk for some infections, with prescribed immunomodulatory (IM) therapies increasing this risk further.…
Abstract Number: 0469 • ACR Convergence 2021
Imaging Characteristics in Patients with Spondyloarthritis Using a Novel Heel Enthesitis Magnetic Resonance Imaging Scoring (HEMRIS) System: Post-hoc Analysis of a Phase 3 Secukinumab Trial
Xenofon Baraliakos¹, Philipp Sewerin², Eugenio De Miguel³, Effie Pournara⁴, Christine Kleinmond⁵, Ankita Shekhawat⁶, Annette Wiedon⁷ and Frank Behrens⁸, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Department and Hiller Research Unit of Rheumatology, Heinrich Heine University Duesseldorf, Duesseldorf, Germany, ³Hospital Universitario La Paz, Madrid, Spain, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵ClinProject GmbH, Eurasburg, Germany, ⁶Novartis Healthcare Private Limited, Hyderabad, India, ⁷Novartis Pharma GmbH, Nürnberg, Germany, ⁸Rheumatology & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Frankfurt/Main, Germany
Background/Purpose: The heel is a frequently affected anatomical site for enthesitis in spondyloarthritis (SpA).1 Recently, the Outcome Measures in Rheumatology (OMERACT) group developed and validated…
Abstract Number: 0822 • ACR Convergence 2021
Local Tolerance of GP2017, an Adalimumab Biosimilar with Low Citrate Concentration Formulation, in Healthy Volunteers and Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis
Piotr Wiland¹, Andrew Blauvelt², Lena Lemke³, Oliver von Richter⁴, Alison Balfour⁴, Fabricio Furlan⁴ and Norman Gaylis⁵, ¹Department of Rheumatology and Internal Medicine, Medical University, Wroclaw, Poland, ²Oregon Medical Research Center, Portland, ³Hexal AG (A Sandoz company), Holzkirchen,Germany, Holzkirchen, Germany, ⁴Hexal AG (A Sandoz company), Holzkirchen, Germany, Holzkirchen, Germany, ⁵Arthritis and Rheumatic Disease Specialties, Aventura, FL
Background/Purpose: Adalimumab (ADL) can be self-administered every 2 weeks as a subcutaneous (s.c.) injection in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis…
Abstract Number: 1315 • ACR Convergence 2021
The Best Cardiovascular Risk Algorithm to Predict the Presence of Carotid Plaque in Psoriatic Arthritis Patients
Natalia Guajardo-Jauregui, Iris Colunga-Pedraza, Jose Azpiri-Lopez, Dionicio Galarza-Delgado, Alejandra Rodriguez-Romero, Diana Flores-Alvarado, Julieta Loya-Acosta, Alejandro Meza-Garza, Jesus Cardenas-de La Garza, Salvador Lugo-Perez and Jessica Castillo-Treviño, Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico
Background/Purpose: Systemic inflammation in psoriatic arthritis (PsA) patients accelerates the process of atherosclerosis; this increases the risk of presenting a major cardiovascular (CV) event than…
Abstract Number: 1336 • ACR Convergence 2021
Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19-Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
Iain McInnes¹, Proton Rahman², Alice Gottlieb³, Elizabeth Hsia⁴, Alexa Kollmeier⁵, Xie Xu⁴, Shihong Sheng⁴, Yusang Jiang⁴, May Shawi⁶, Soumya Chakravarty⁷, Désirée van der Heijde⁸ and Philip Mease⁹, ¹University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ²Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC, La Jolla, CA, ⁶Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁷Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, ⁸Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: Guselkumab (GUS), an anti-IL-23p19-subunit mAb dosed every 4 or 8 weeks (Q4W or Q8W), demonstrated efficacy for joint and skin symptoms, inhibition of structural…
Abstract Number: 1353 • ACR Convergence 2021
Whole Blood Transcriptional Changes Following Treatment with Filgotinib in Patients with Psoriatic Arthritis
Dafna Gladman¹, Yihua Liu², Oh Kyu Yoon², Mona Trivedi², René Galien³, Robin Besuyen⁴, Vlad Malkov², Angie Hertz² and Vinod Chandran¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²Gilead Sciences, Foster City, CA, ³Galapagos NV, Romainvulle, France, ⁴Galapagos BV, Leiden, Netherlands
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory autoimmune disease characterized by musculoskeletal and skin inflammation. Selective inhibition of Janus kinase 1 (JAK1) has the…
Abstract Number: 1713 • ACR Convergence 2021
Risk of Serious Infections in Offspring Exposed in Utero to Ustekinumab or Vedolizumab
Jonah Gorodensky¹, Sasha Bernatsky¹, Waqqas Afif¹, Yvan St-Pierre², Kristian Filion¹ and Evelyne Vinet³, ¹McGill University, Montréal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Ustekinumab, an IL-12/23 inhibitor, is indicated in adult patients with inflammatory bowel disease (IBD), psoriasis (PsO), and psoriatic arthritis (PsA) and vedolizumab, an α4β7…
Abstract Number: 1788 • ACR Convergence 2021
Improving Care and Capacity Through Capturing and Recording Patient Reported Outcomes with Digital Solutions in Spondyloarthritis
Antoni Chan¹, Kathryn Rigler¹ and Liz van Rossen², ¹Royal Berkshire NHS Foundation Trust, Reading, United Kingdom, ²East Kent NHS Foundation Trust, Kent, United Kingdom
Background/Purpose: Patient-reported outcomes (PROs) have always been at the forefront for the assessment of spondyloarthritis (SpA) which includes axial Spa (axSpA) and psoriatic arthritis (PsA).…
Abstract Number: 1805 • ACR Convergence 2021
Low Rates of Radiographic Progression with 2 Years of Guselkumab (TREMFYA®), a Selective Inhibitor of the Interleukin-23p19 Subunit: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study of Biologic-naïve Patients with Active Psoriatic Arthritis
Philip Mease¹, Alice Gottlieb², Iain McInnes³, Proton Rahman⁴, Alexa Kollmeier⁵, Xie Xu⁶, Yusang Jiang⁶, Shihong Sheng⁶, May Shawi⁷, Soumya Chakravarty⁸, Frederic Lavie⁹ and Désirée van der Heijde¹⁰, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ⁴Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁵Janssen Research & Development, LLC, La Jolla, CA, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁸Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, ⁹Janssen Global Services, LLC, Horsham, PA, ¹⁰Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands
Background/Purpose: Guselkumab (GUS), an IL-23p19-subunit inhibitor, is efficacious in treating patients (pts) with psoriasis and psoriatic arthritis (PsA). In the Phase 3, double-blind, placebo (PBO)-controlled…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].